Bull Notes Keep Coming For These 2 Drugmakers

Analysts see much more upside for PCRX and RARE stocks

Managing Editor
Aug 3, 2018 at 10:03 AM
facebook twitter linkedin

Two drug stocks received some bullish analyst attention this morning. Analysts believe both drugmakers Pacira Pharmaceuticals Inc (NASDAQ:PCRX) and Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) are poised to keep climbing in the near future. 

PCRX Eyeing An Extended Rally

Pacira stock is up 4.4% to trade at $44.90, after three brokerages issued price-target hikes, including to $52 from $48 at H.C. Wainwright. The drug name is fresh off an upbeat earnings report yesterday, and the continued momentum today puts the shares at their highest mark since January, putting the stock right near its year-to-date breakeven point.

A short squeeze could drive PCRX even higher. Short interest fell by 16% in the two most recent reporting periods, yet the 4.01 million shares sold short represent nearly 13% of the equity's total available float. It would take seven days for shorts to buy back their positions, at the stock's average daily trading volume. 

RARE Extends Pullback Despite Bull Note

Ultragenyx stock is down 2.6% to trade at $77.52, despite Raymond James upping its price target by $15 to $86. The biotech concern also reported smaller-than-expected quarterly loss yesterday, which prompted three additional price-target hikes as well. Today's drop has RARE stock breaching its 50-day moving average, a trendline that briefly contained a pullback from the security's annual high of $87.33 on July 17.

A short squeeze is also in play for RARE. Short interest dropped off 2% in the most recent reporting period, but the 4.98 million shares sold short still represent almost 12% of the stock's total available float, and nearly 13 days' worth of pent-up buying power, based on average trading volumes.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial


Special Offers from Schaeffer's Trading Partners